WinstonWınston
Back
Global Health Limited logo

Global Health Limited

GLH.AX
16
Medical - Healthcare Information Services · Healthcare
Price
A$0.06
+0.00 (+0.00%)
Market Cap
A$3.5M
Exchange
Australian Securities Exchange
Winston Score
16
Winston is worried
Weak fundamentals across most pillars.
Data as of Aug 23, 2026 · filings through Dec 31, 2025
How the score breaks down
Quality
Weak
Growth
Weak
Cash Flow
Weak
Stability
Data not available
Valuation
Weak
Dividends
Weak

Share count rising — dilution

+37.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 42.4M (2021) → 58.2M (2025)

Winston Score History

The full picture

Global Health Limited is a small Australian software company that builds digital tools for the healthcare industry. Its main products include electronic medical records, patient management systems, and secure messaging platforms used by hospitals, clinics, aged care facilities, and allied health providers across Australia. The company focuses on helping healthcare organizations store, share, and manage patient information more efficiently.

Global Health makes money by selling software licenses and charging ongoing subscription fees for its platforms, giving it a recurring revenue base. It operates almost entirely within Australia, and its gross margin of around 62% reflects the relatively low cost of delivering software once it is built. The company's moat comes from the sticky nature of healthcare software — switching systems is costly and disruptive for medical providers. The key growth driver is Australia's continued push toward digitizing health records and improving data sharing across the healthcare system, though competition from larger domestic and international health IT vendors remains a meaningful risk.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-17.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+9.3% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

A$2M/ year

Declining (-22% vs prior year)

24.2% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

11.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 years

A$1M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

A$1M cash & investments at current burn rate

Revenue declining

Global Health Limited's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
-14.8%
Thin — -14.8% gross margin
Profit after running costs
Operating Margin
-26.3%
Losing money on operations — -26.3%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-5.8%
Shrinking sales (-5.8% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-4.0%
Burning cash (-4.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
68.1x
Expensive — P/E 68.1

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
0.04%
Small dividend — 0.04% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial